The use of IVIG in neurological disease.
The studies cited herein highlight the potential benefits of IVIG therapy in a group of neurological disorders that are associated with aberrant immune responses. Indeed, all of the disorders discussed, except epilepsy, are associated with autoreactivity. The trials are preliminary and short-term and, except for idiopathic CIDP, uncontrolled. Interpretation of the findings of these uncontrolled studies is complicated by the fact that the natural history of all of these disorders is to show fluctuations. IVIG appears to be a potentially useful and safe agent in the treatment of patients with MG, intractable epilepsy, MS, and CIDP. Its place in the therapeutic approach to these neurological diseases must await the completion of controlled trials. Since other therapeutic modalities have already proven to be useful in several of these disorders, it will be important to determine if IVIG is more efficacious, safer, and more cost-effective. It is also worth considering whether the combination of IVIG and any of these more traditional approaches would provide added therapeutic benefit.
Levinson
A I
AI
University of Pennsylvania School of Medicine, Philadelphia.
D001327:Autoimmune Diseases / Q000628:therapy; D004827:Epilepsy / Q000628:therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D009157:Myasthenia Gravis / Q000628:therapy; D009422:Nervous System Diseases / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D010523:Peripheral Nervous System Diseases / Q000628:therapy; D011129:Polyradiculoneuropathy / Q000628:therapy
D016756:Immunoglobulins, Intravenous